AUTHORS
Kazuhiro Noguchi, MD.,PhD., Carlo Castruccio Castracani, PharmD, PhD2, Jean Ann Maguire3, Alyssa Gagne4, Wei Tong, PhD5, Giulia Pavani, PhD6, Stefano Rivella, PhD7
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
ABSTRACT
Background
X-linked sideroblastic anemia (XLSA) is the most common form of congenital sideroblastic anemia, caused by germline mutations in ALAS2, which encodes the erythroid-specific 5-aminolevulinate synthase, the first and rate-limiting enzyme of heme biosynthesis. Loss-of-function ALAS2 mutations impair heme production, causing hypochromic anemia with ring sideroblasts. Currently, the only curative therapy for XLSA is allogeneic hematopoietic stem cell transplantation, which carries substantial risks. Lentiviral gene therapy delivering ALAS2 could offer a curative, autologous alternative that avoids the immunological complications of allogeneic transplantation; however, ALAS2 overexpression may increase the production of metal-free protoporphyrin IX (mf-PPIX), leading to hyperphotosensitivity and hepatotoxicity.
Methods
We engineered seven lentiviral vectors (LVs) expressing human ALAS2 at varying levels. X-ALAS2-LV carries a wild-type ALAS2 allele flanked by 5' and 3' HBB untranslated regions (UTRs). M1-, M2-, and M3-ALAS2-LV carry hypomorphic ALAS2 alleles (D263N, R375C, and R411H, respectively) with the same HBB UTRs, to attenuate expression. U3-, U5-, and U3/5-ALAS2-LV retain a wild-type ALAS2 allele but replace the 3', 5', or both HBB UTRs with the corresponding ALAS1 UTRs, enabling heme-dependent negative feedback analogous to endogenous ALAS1 regulation. We generated an inducible XLSA mouse model by deleting a floxed Alas2 allele (Alas2fl/Y) using Cre mRNA delivered via targeted lipid nanoparticles. Mf-PPIX production was measured for each LV in transduced K562 clones harboring an ALAS2 R452C mutation and in XLSA mice transplanted with LV-transduced bone marrow. Five months post-transplantation, we assessed hematologic parameters, erythroid differentiation, iron-metabolism markers, and mitochondrial function using flow cytometry.
Results
As expected, X-ALAS2-LV produced the highest mf-PPIX levels in ALAS2-mutant K562 clones. In XLSA mice, all seven LVs significantly increased red blood cell output, but only M2-, U5-, and X-ALAS2-LV normalized hemoglobin levels and eliminated mortality. However, X-ALAS2-LV also led to the highest accumulation of mf-PPIX and mitochondrial iron overload. M2-ALAS2-LV and U5-ALAS2-LV both improved splenomegaly more effectively than X-ALAS2-LV, but M2-ALAS2-LV produced the greatest mitochondrial superoxide levels. U5-ALAS2-LV uniquely sustained therapeutic ALAS2 expression while minimizing mitochondrial iron accumulation and oxidative stress, identifying it as the most physiological vector. No significant differences were observed in erythroblast composition—including the ratios of proerythroblast, basophilic, polychromatic, orthochromatic erythroblasts, and reticulocytes—among M2-, U5-, and XALAS2-LV groups. Organ weights of the heart, kidney, and liver were also comparable across groups, except for the spleen. To assess hyperphotosensitivity resulting from mf-PPIX accumulation, UV-induced cutaneous photosensitivity assays are currently underway.
Summary/Conclusion
We developed a panel of ALAS2-expressing lentiviral vectors that rescue the XLSA disease phenotype, demonstrating the feasibility of gene therapy for this disorder. U5-ALAS2-LV, which couples wild-type ALAS2 with ALAS1 UTR-mediated feedback regulation, normalized hemoglobin levels and eliminated mortality without inducing mitochondrial iron accumulation or oxidative stress, making it the leading candidate for clinical translation in XLSA gene therapy.
DISCLOSURES
Kazuhiro Noguchi, MD.,PhD.: No relevant conflicts of interest to declare.